Targeted-release budesonide for treating primary IgA nephropathy

  • Technology appraisal guidance
  • TA1128
  • Published: 

Suggested remit: To appraise the clinical and cost effectiveness of Budesonide targeted-release within its marketing authorisation for treating IgA nephropathy.

This page was last updated: